Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 15501 - 15525 of 15577 in total
Experimental
Experimental
Experimental
Matched Iupac: … 2-{[2-(propan-2-yl)phenoxy]methyl}-4,5-dihydro-1H-imidazole …
Dextromethadone is under investigation in clinical trial NCT00588640 (Study of D-Methadone in Patients With Chronic Pain).
Investigational
DG051 is a novel small-molecule inhibitor of leukotriene A4 hydrolase (LTA4H), the protein made by one of the genes in the leukotriene pathway that has been shown to link to risk of heart attack. DG051 is designed to decrease risk of heart attack by decreasing the production of leukotriene B4...
Investigational
Matched Description: … attack by decreasing the production of leukotriene B4 (LTB4), an end product of the leukotriene pathway and
Rivoglitazone (INN) is a thiazolidinedione undergoing research for use in the treatment of type 2 diabetes. It is being developed by Daiichi Sankyo Co.
Experimental
Investigational
Matched Iupac: … 5-({4-[(6-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl)methoxy]phenyl}methyl)-1,3-thiazolidine-2,4-dione …
Matched Description: … Rivoglitazone (INN) is a thiazolidinedione undergoing research for use in the treatment of type 2 diabetes …
Tucaresol has been used in trials studying the treatment of HIV Infections.
Investigational
Matched Iupac: … 4-[(2-formyl-3-hydroxyphenoxy)methyl]benzoic acid …
XMT-1001 is a polymer-based prodrug of camptothecin (CPT), a well-characterized topoisomerase I inhibitor with potent anti-tumor activity. It is a water-soluble macromolecular conjugate of camptothecin (CPT). In this novel CPT pro-drug, CPT is conjugated with a 70 kDa biodegradable hydrophilic polyacetal, poly (1-hydroxymethylene hydroxylmethylformal). XMT-1001 has demonstrated an improved therapeutic...
Investigational
Matched Description: … XMT-1001 has demonstrated an improved therapeutic window as compared with CPT and irinotecan in human …
Nelotanserin has been used in trials studying the treatment of Lewy Body Dementia, Visual Hallucinations, Dementia With Lewy Bodies, and REM Sleep Behavior Disorder. It is a highly selective antagonist at the 5-HT2A serotonin receptor. It increases non-REM sleep, the most restorative phase of the sleep cycle, without sacrificing REM...
Investigational
Matched Description: … trials studying the treatment of Lewy Body Dementia, Visual Hallucinations, Dementia With Lewy Bodies, and
LI 301 is an orally bio-available compound delivered in a fast melt mechanism with taste masking enabling it to be taken anytime without water. It has a novel mode of action combining both the light effect of a Selective Serotonin Reuptake Inhibitor ("SSRI")(most likely antagonistic at 5HT1a receptors) and antagonism...
Investigational
Matched Description: … of a Selective Serotonin Reuptake Inhibitor ("SSRI")(most likely antagonistic at 5HT1a receptors) and
Experimental
Vet approved
Matched Iupac: … {6-[(1E)-2-(5-nitrofuran-2-yl)ethenyl]pyridin-2-yl}methanol …
Ondelopran has been used in trials studying the treatment of Alcohol Dependence.
Investigational
Matched Iupac: … 6-[2-fluoro-4-({[2-(oxan-4-yl)ethyl]amino}methyl)phenoxy]pyridine-3-carboxamide …
NLX-P101, gene therapy is developed by Neurologix to treat Parkinson’s disease. The gene is glutamic acid decarboxylase (GAD), whose product synthesizes the major inhibitory neurotransmitter in the brain, (gamma)-aminobutyric acid (GABA), and targets the subthalamic nucleus (STN), which is overactive in patients with Parkinson’s disease. NLX-P101 is being evaluated as...
Investigational
Matched Description: … product synthesizes the major inhibitory neurotransmitter in the brain, (gamma)-aminobutyric acid (GABA), and
Experimental
Matched Iupac: … (2R)-2-[(1R)-1-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]acetamido]-2-oxoethyl …
Experimental
Vet approved
Matched Iupac: … methyl N-{[(methoxycarbonyl)amino]({[2-(2-methoxyacetamido)-4-(phenylsulfanyl)phenyl]imino})methyl}carbamate …
CG0070 is investigated in clinical trials for treating bladder cancer. CG0070 is a solid. CG0070 can potentially destroy cancer cells by two different mechanisms: direct cell killing by the virus and immune-mediated cell killing stimulated by GM-CSF. CG0070, an oncolytic virus therapy with specificity for multiple cancers, has been evaluated...
Investigational
Matched Description: … can potentially destroy cancer cells by two different mechanisms: direct cell killing by the virus and
Lifirafenib is under investigation in clinical trial NCT03641586 (The Study of BGB-283 in Chinese Subjects With Local Advanced or Metastatic Malignant Solid Tumor).
Investigational
Matched Iupac: … 7,9-trien-9-yl]oxy}-1,2,3,4-tetrahydro-1,8-naphthyridin-2-one ... 5-{[(2R,3R,4S)-3-[6-(trifluoromethyl)-1H-1,3-benzodiazol-2-yl]-5-oxatricyclo[4.4.0.0^{2,4}]deca-1(6), …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
Ivarmacitinib (SHR0302) is a selective inhibitor of Janus kinase 1 (JAK1) under investigation for the treatment of various immuno-inflammatory conditions. While ivarmactinib has yet to receive marketing authorization, as of February 2022 clinical trials are ongoing or completed evaluating its use in atopic dermatitis,[L40604,L40619,L40629] ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis,...
Experimental
Investigational
Matched Iupac: … 1,2,4-thiadiazol-5-yl)-5-[methyl({7H-pyrrolo[2,3-d]pyrimidin-4-yl})amino]-octahydrocyclopenta[c]pyrrole-2- …
Matched Description: … graft-versus-host disease,[A245653,L40599] vitiligo,[L40609] ulcerative colitis,[L40614] alopecia areata,[L40624] and
Henatinib has been used in trials studying the treatment of Advanced Solid Cancer.
Investigational
Matched Iupac: … [3,2-c]azepin-2-yl}methylidene)-2,3-dihydro-1H-indol-2-one ... (3Z)-5-fluoro-3-({5-[(2R)-2-hydroxy-3-(morpholin-4-yl)propyl]-3-methyl-4-oxo-1H,4H,5H,6H,7H,8H-pyrrolo …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
Siagoside (Sygen, AGF 2) has been investigated for the treatment of Parkinson Disease. It is a naturally occurring substance in the nerve cell’s membrane that is thought to play a role in cell growth, development, and repair. Siagoside completed phase 2 trials for parkinson's disease (PD) treatment. Sygen appears to...
Investigational
Matched Iupac: … oxane-2,2'-pyrano[3,4-b][1,4]dioxin]-3'-oneoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-3-hydroxyoctadec ... -4-en-2-yl]octadecanamide ... 3-acetamido-5-hydroxy-6-(hydroxymethyl)-4-{[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2- ... yl]oxy}oxan-2-yl]oxy}-4-hydroxy-7'-(hydroxymethyl)-6-[(1R,2R)-1,2,3-trihydroxypropyl]-hexahydrospiro[ …
Matched Description: … substance in the nerve cell’s membrane that is thought to play a role in cell growth, development, and ... Siagoside completed phase 2 trials for parkinson's disease (PD) treatment. ... Siagoside (Sygen, AGF 2) has been investigated for the treatment of Parkinson Disease. …
Experimental
Matched Iupac: … 6-[2-(4-hydroxy-3-nitrophenyl)acetamido]hexanoate …
Experimental
Matched Iupac: … 6-[2-(4-hydroxy-3-iodo-5-nitrophenyl)acetamido]hexanoate …
Displaying drugs 15501 - 15525 of 15577 in total